{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:08:08Z","timestamp":1792728488721,"version":"4.5.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The rise of high-potency opioids such as fentanyl makes buprenorphine initiation challenging due to the risks of precipitated withdrawal, prompting the exploration of strategies, such as low-dose initiation (LDI) of buprenorphine. However, no comparative studies on LDI outcomes exist.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate outpatient outcomes associated with 2 LDI protocols of buprenorphine among individuals with opioid use disorder (OUD) using fentanyl.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study analyzed data on adults with OUD who self-reported daily fentanyl use and underwent buprenorphine initiation using LDI. Data were extracted from the electronic health records of 2 substance use disorder treatment clinics using a specialty behavioral health pharmacy in San Francisco, California, from May 2021 to November 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Type of LDI protocol selected by individuals: 4-day or 7-day protocol.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was successful buprenorphine initiation, defined as self-reported LDI completion and pickup of a refill maintenance prescription, and buprenorphine retention. Logistic regression with generalized estimating equations assessed associations between LDI protocol (4-day vs 7-day) and successful initiation, adjusting for multiple attempts, age, gender identity, race and ethnicity, and housing status. Kaplan-Meier survival curves were used to estimate buprenorphine retention, and survival curves were adjusted using a fitted Cox proportional hazards regression model.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 126 individuals (median [IQR] age, 35 [29-44] years; 90 identified as men [71%]; 26 [21%] identified as Black or African American, 20 [16%] as Latine, and 66 [52%] as White individuals) with 175 initiation attempts were included. Across attempts, 72 (41%) had a 4-day LDI protocol and 103 (59%) had a 7-day protocol. Initiation was successful in 60 attempts (34%), including 27 (38%) among 4-day protocol and 29 (28%) among 7-day protocol attempts. Buprenorphine retention rate at 28 days was 21% for a 4-day protocol and 18% for a 7-day protocol. Logistic regression found no significant differences between LDI protocols and successful initiation, while repeated LDI attempts had lower odds of success (second attempt: adjusted odds ratio [AOR], 0.30 [95% CI, 0.14-0.66]; third or more attempt: AOR, 0.22 [95% CI, 0.09-0.53]). Unadjusted and adjusted survival models did not detect a significant difference in retention between LDI protocol types.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study found that among people with OUD using fentanyl and attempting outpatient LDI of buprenorphine, successful buprenorphine initiation and retention rates were low. Future studies should examine interventions to improve LDI success and increase buprenorphine uptake and retention.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.56253","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T16:32:42Z","timestamp":1737736362000},"page":"e2456253","source":"Crossref","is-referenced-by-count":33,"title":["Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl"],"prefix":"10.1001","volume":"8","author":[{"given":"Leslie W.","family":"Suen","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine at San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Y.","family":"Chiang","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine at San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L. H.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.","family":"Soran","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Geier","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah R.","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Neuhaus","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet J.","family":"Myers","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly R.","family":"Knight","sequence":"additional","affiliation":[{"name":"Department of Humanities and Social Sciences, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Bazazi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip O.","family":"Coffin","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"zoi241579r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019\u201d.","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"12","key":"zoi241579r2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2021.1169","article-title":"Continued increases in overdose deaths related to synthetic opioids: implications for clinical practice.","volume":"325","author":"Baldwin","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"zoi241579r4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1017\/S146114570700836X","article-title":"Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study.","volume":"11","author":"Soyka","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"zoi241579r5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.addbeh.2010.01.001","article-title":"Unobserved versus observed office buprenorphine\/naloxone induction: a pilot randomized clinical trial.","volume":"35","author":"Gunderson","year":"2010","journal-title":"Addict Behav"},{"issue":"4","key":"zoi241579r6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.","volume":"355","author":"Fiellin","year":"2006","journal-title":"N Engl J Med"},{"key":"zoi241579r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111053","article-title":"Health risks associated with smoking versus injecting fentanyl among people who use drugs in California.","volume":"255","author":"Megerian","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"zoi241579r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109003","article-title":"Transition from injecting opioids to smoking fentanyl in San Francisco, California.","volume":"227","author":"Kral","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi241579r12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl.","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"5","key":"zoi241579r13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40261-021-01032-7","article-title":"The pharmacology of buprenorphine microinduction for opioid use disorder.","volume":"41","author":"De Aquino","year":"2021","journal-title":"Clin Drug Investig"},{"key":"zoi241579r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108140","article-title":"Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.","volume":"119","author":"Jakubowski","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"zoi241579r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108778","article-title":"Cascade of care for office-based buprenorphine treatment in Bronx community clinics.","volume":"139","author":"Khalid","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"zoi241579r16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era.","volume":"16","author":"Sue","year":"2022","journal-title":"J Addict Med"},{"issue":"6","key":"zoi241579r17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids.","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"key":"zoi241579r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108147","article-title":"Protracted renal clearance of fentanyl in persons with opioid use disorder.","volume":"214","author":"Huhn","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi241579r19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/ADM.0000000000001185","article-title":"Fentanyl absorption, distribution, metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl.","volume":"17","author":"Bird","year":"2023","journal-title":"J Addict Med"},{"issue":"2","key":"zoi241579r20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/dar.13394","article-title":"Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: a case series.","volume":"41","author":"Shearer","year":"2022","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"zoi241579r21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/dar.13113","article-title":"Use of a novel prescribing approach for the treatment of opioid use disorder: buprenorphine\/naloxone micro-dosing - a case series.","volume":"39","author":"Brar","year":"2020","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"zoi241579r22","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/ADM.0000000000000864","article-title":"Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis.","volume":"16","author":"Button","year":"2022","journal-title":"J Addict Med"},{"issue":"4","key":"zoi241579r23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajad.13135","article-title":"Microinduction of buprenorphine\/naloxone: a review of the literature.","volume":"30","author":"Ahmed","year":"2021","journal-title":"Am J Addict"},{"issue":"1","key":"zoi241579r24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13722-021-00244-8","article-title":"Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review.","volume":"16","author":"Adams","year":"2021","journal-title":"Addict Sci Clin Pract"},{"key":"zoi241579r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209261","article-title":"Low-dose buprenorphine initiation and treatment continuation among hospitalized patients with opioid dependence: a retrospective cohort study.","volume":"158","author":"Hayes","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"4","key":"zoi241579r26","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1097\/ADM.0000000000001154","article-title":"The Howard Street method: a community pharmacy-led low dose overlap buprenorphine initiation protocol for individuals using fentanyl.","volume":"17","author":"Noel","year":"2023","journal-title":"J Addict Med"},{"issue":"5","key":"zoi241579r27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/ADM.0000000000000961","article-title":"Rapid overlap initiation protocol using low dose buprenorphine for opioid use disorder treatment in an outpatient setting: a case series.","volume":"16","author":"Suen","year":"2022","journal-title":"J Addict Med"},{"issue":"8","key":"zoi241579r28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi241579r30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12954-024-00998-9","article-title":"Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study.","volume":"21","author":"Jones","year":"2024","journal-title":"Harm Reduct J"},{"issue":"12","key":"zoi241579r31","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1093\/aje\/kwad149","article-title":"Latino? Latinx? Latine? A call for inclusive categories in epidemiologic research.","volume":"192","author":"Miranda","year":"2023","journal-title":"Am J Epidemiol"},{"issue":"4","key":"zoi241579r32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/ADM.0000000000001155","article-title":"Association of urine fentanyl concentration with severity of opioid withdrawal among patients presenting to the emergency department.","volume":"17","author":"Thakrar","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"zoi241579r33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/ADM.0000000000000947","article-title":"Low dose buprenorphine induction with full agonist overlap in hospitalized patients with opioid use disorder: a retrospective cohort study.","volume":"16","author":"Bhatraju","year":"2022","journal-title":"J Addict Med"},{"issue":"6","key":"zoi241579r34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/ADM.0000000000001214","article-title":"Low-dose initiation of buprenorphine in hospitalized patients on full agonist opioid therapy: a retrospective observational study.","volume":"17","author":"Schult","year":"2023","journal-title":"J Addict Med"},{"issue":"1","key":"zoi241579r36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/ADM.0000000000001246","article-title":"Dispensing methadone at hospital discharge: one hospital\u2019s approach to implementing the \u201c72-hour rule\u201d change.","volume":"18","author":"Skogrand","year":"2024","journal-title":"J Addict Med"},{"key":"zoi241579r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109497","article-title":"Bridge clinic implementation of \u201c72-hour rule\u201d methadone for opioid withdrawal management: impact on opioid treatment program linkage and retention in care.","volume":"236","author":"Taylor","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi241579r38","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/ajhp\/zxad288","article-title":"Operationalizing the new DEA exception: a novel process for dispensing of methadone for opioid use disorder at discharge from acute care settings.","volume":"81","author":"Bowman","year":"2024","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"zoi241579r39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/ADM.0000000000001281","article-title":"Novel uses of methadone under the \u201c72-hour rule\u201d to facilitate transitions of care and low-dose buprenorphine induction in an outpatient bridge clinic.","volume":"18","author":"Shahlapour","year":"2024","journal-title":"J Addict Med"},{"issue":"4","key":"zoi241579r40","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11606-007-0129-0","article-title":"Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.","volume":"22","author":"Moore","year":"2007","journal-title":"J Gen Intern Med"},{"issue":"3","key":"zoi241579r41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi241579r42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13722-019-0149-1","article-title":"Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.","volume":"14","author":"Carter","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"7","key":"zoi241579r43","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1111\/add.15862","article-title":"Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.","volume":"117","author":"Gomes","year":"2022","journal-title":"Addiction"},{"issue":"5","key":"zoi241579r44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1037\/a0037550","article-title":"A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: findings from a retrospective multisite study.","volume":"22","author":"Proctor","year":"2014","journal-title":"Exp Clin Psychopharmacol"},{"key":"zoi241579r45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder.","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"key":"zoi241579r46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ypmed.2016.08.008","article-title":"A review of the literature on contingency management in the treatment of substance use disorders, 2009-2014.","volume":"92","author":"Davis","year":"2016","journal-title":"Prev Med"},{"issue":"4","key":"zoi241579r47","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jama.2022.24324","article-title":"Sequential, multiple assignment, randomized trial designs.","volume":"329","author":"Kidwell","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"zoi241579r48","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1177\/09622802221095673","article-title":"Design and analysis of partially randomized preference trials with propensity score stratification.","volume":"31","author":"Wang","year":"2022","journal-title":"Stat Methods Med Res"},{"key":"zoi241579r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108717","article-title":"Opioid use disorder treatment for people experiencing homelessness: a scoping review.","volume":"224","author":"McLaughlin","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi241579r50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.therap.2020.05.007","article-title":"Prolonged-release buprenorphine formulations: perspectives for clinical practice.","volume":"75","author":"Chappuy","year":"2020","journal-title":"Therapie"},{"issue":"7","key":"zoi241579r51","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.20702","article-title":"Extended-release 7-day injectable buprenorphine for patients with minimal to mild opioid withdrawal.","volume":"7","author":"D\u2019Onofrio","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi241579r52","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s40262-023-01288-6","article-title":"Population pharmacokinetic analysis supports initiation treatment and bridging from sublingual buprenorphine to subcutaneous administration of a buprenorphine depot (CAM2038) in the treatment of opioid use disorder.","volume":"62","author":"Bj\u00f6rnsson","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"zoi241579r53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6108","article-title":"Incidence of precipitated withdrawal during a multisite emergency department-initiated buprenorphine clinical trial in the era of fentanyl.","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi241579r54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11634","article-title":"Analysis of stimulant prescriptions and drug-related poisoning risk among persons receiving buprenorphine treatment for opioid use disorder.","volume":"5","author":"Mintz","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi241579r8","volume-title":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for Opioid Use Disorder Save Lives","author":"Leshner","year":"2019"},{"key":"zoi241579r29","volume-title":"Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: A Treatment Improvement Protocol","author":"Center for Substance Abuse Treatment","year":"2004"},{"key":"zoi241579r35","volume-title":"StatPearls","author":"Ortiz","year":"2023"},{"key":"zoi241579r3","unstructured":"Ahmad? FB, Cisewski? JA, Rossen? LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. Accessed September 18, 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi241579r7","unstructured":"Removal of DATA waiver (X-Waiver) requirement. Substance Abuse and Mental Health Services Administration. January 25, 2023. Accessed March 13, 2023. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/removal-data-waiver-requirement"},{"key":"zoi241579r11","unstructured":"Anderson? N, McMahan? V, Coffin? PO. Substance use trends in San Francisco through 2022. Center on Substance Use and Health, Department of Public Health, City and County of San Francisco. 2023. Accessed October 15, 2024. https:\/\/www.csuhsf.org\/_files\/ugd\/91710f_ea77b3b62d81455c8143aa2f97b2d5d5.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2829504\/suen_2025_oi_241579_1736971374.62293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T16:32:47Z","timestamp":1737736367000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2829504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56253","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}